Skip to main content
OpenTrials

Clinical trial condition

Recurrent Endometrial Clear Cell Adenocarcinoma

Explore clinical trials studying Recurrent Endometrial Clear Cell Adenocarcinoma. Study availability and eligibility vary by location and protocol.

3 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Recurrent Endometrial Clear Cell Adenocarcinoma trial results

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

NCT05950464

Conditions
Endometrial Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +18 more
Locations
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612

Conditions
Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +30 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 397 locations
View Trial Details

Related conditions